These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17176210)

  • 1. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.
    Wang Z; Allen JM; Riddell SR; Gregorevic P; Storb R; Tapscott SJ; Chamberlain JS; Kuhr CS
    Hum Gene Ther; 2007 Jan; 18(1):18-26. PubMed ID: 17176210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
    Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
    Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A canine minidystrophin is functional and therapeutic in mdx mice.
    Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
    Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
    Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ
    Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model.
    Wang Z; Halbert CL; Lee D; Butts T; Tapscott SJ; Storb R; Miller AD
    Gene Ther; 2014 Apr; 21(4):363-70. PubMed ID: 24500525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
    Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
    J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle.
    Jiang Z; Schiedner G; Gilchrist SC; Kochanek S; Clemens PR
    Gene Ther; 2004 Oct; 11(19):1453-61. PubMed ID: 15269713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.
    Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D
    Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs.
    Shin JH; Yue Y; Srivastava A; Smith B; Lai Y; Duan D
    Hum Gene Ther; 2012 Feb; 23(2):202-9. PubMed ID: 21967249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.
    Hakim CH; Kumar SRP; Pérez-López DO; Wasala NB; Zhang D; Yue Y; Teixeira J; Pan X; Zhang K; Million ED; Nelson CE; Metzger S; Han J; Louderman JA; Schmidt F; Feng F; Grimm D; Smith BF; Yao G; Yang NN; Gersbach CA; Chen SJ; Herzog RW; Duan D
    Nat Commun; 2021 Nov; 12(1):6769. PubMed ID: 34819506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local gene delivery and methods to control immune responses in muscles of normal and dystrophic dogs.
    Wang Z; Tapscott SJ; Storb R
    Methods Mol Biol; 2011; 709():265-75. PubMed ID: 21194034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice.
    Heller KN; Montgomery CL; Shontz KM; Clark KR; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2015 Oct; 26(10):647-56. PubMed ID: 26076707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle.
    Ohshima S; Shin JH; Yuasa K; Nishiyama A; Kira J; Okada T; Takeda S
    Mol Ther; 2009 Jan; 17(1):73-80. PubMed ID: 18941441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
    Blankinship MJ; Gregorevic P; Chamberlain JS
    Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.
    Zygmunt DA; Crowe KE; Flanigan KM; Martin PT
    Hum Gene Ther; 2017 Sep; 28(9):737-746. PubMed ID: 28042944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.